Original disease of the recipient

Area of Science:

• Nephrology
• Immunology
• Transplantation Medicine

Background:

• Graft survival rates in organ transplantation are influenced by various factors including immunosuppression, donor type, and patient disease.
• Trends in kidney transplantation indicate a rising proportion of diabetic recipients and a decline in those with glomerulonephritis or pyelonephritis since 1970.

Purpose of the Study:

• To evaluate the impact of Cyclosporine A (CsA) on graft survival rates in cadaveric versus living donor kidney transplants.
• To assess the influence of pretransplant blood transfusions and HLA matching on transplant outcomes.
• To analyze trends in kidney transplant indications over time.

Main Methods:

• Retrospective analysis of kidney transplant data.
• Comparison of graft survival rates between CsA-treated and non-CsA-treated groups.
• Evaluation of factors including donor type (cadaveric vs. living), pretransplant transfusions, and HLA antigen matching (specifically HLA-B and DR).

Main Results:

• CsA significantly improved one-year graft survival in cadaver donor transplants (14% increase), overcoming original disease effects, except in Systemic Lupus Erythematosus (SLE) patients.
• CsA showed a much smaller benefit in living donor transplants (2-4% increase).
• Pretransplant blood transfusions demonstrated a beneficial effect across most disease groups.
• HLA matching, particularly for HLA-B and DR antigens, correlated with increased graft survival rates.

Conclusions:

• CsA is a highly effective immunosuppressant for improving cadaveric kidney transplant outcomes.
• Pretransplant blood transfusions and HLA matching are important adjuncts for enhancing graft survival.
• Shifting trends in transplant indications highlight the evolving landscape of kidney disease management.